Media
Careers
Contacts
CBP - Pioneering and developing Bi-targeting XDC technology
Pioneering and developing Bi-targeting XDC technology
Contacts
Who We Are
About CBP
Our Culture
Leadership
Our History
Science & Innovation
Approach
Platforms
World of Bi-XDC
Pipeline
Pipeline
Clinical Trials
Publications
For Patient
Patient Safety
Clinical Sites
Toggle menu
CBP-1019-102
CBP
>
CBP-1019-102
CBP-1019-102
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand-Drug Conjugate CBP-1019 in Patients with Advanced Thoracic Tumors.
Ask to Join
Locations
Shanghai Chest Hospital
Shanghai,China
Recruiting
Zhejiang Cancer Hospital
Hangzhou,China
Recruiting
Union Hospital Tong JI Medical college Huazhong University of Science And Technology
Wuhan,China
Recruiting